CEO Sets Strides For Growth With Endo Execs

Stelis Signals Listing, Focus Shift

 
• By Vibha Ravi
  
Generate a summary of this article
Listen to this article
Beta

Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing. 

A businessman appoints a leader to the head of the team. Creation of an effective teams of specialists for the implementation of a new project. HR recruiting. Management appointment. nepotism
Strides' CEO Has Set Up A High-Powered Team To Drive Growth • Source: Shutterstock

Like a soccer team manager, CEO and managing director R Ananthanarayanan is carefully choosing the players on his squad at Strides Pharma Science Limited. Having spent nearly 13 months getting a feel of the company and the competitive field, he has now picked two senior executives from Endo International plc to help implement a strategy that involves a focus on US and other regulated markets for future growth.

Endo’s former executive vice president and chief operating officer Terrance Coughlin is set to join Strides Pharma as CEO-US, while...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.